A bold shift from defensive to aggressive
29/09/25 -"Genmab is strategically acquiring Merus to expand its late-stage portfolio with head and neck cancer treatments, addressing anticipated declines in Darzalex sales by the end of the decade. Although ..."
Pages
50
Language
English
Published on
29/09/25
You may also be interested by these reports :
29/09/25
Genmab is strategically acquiring Merus to expand its late-stage portfolio with head and neck cancer treatments, addressing anticipated declines in ...
24/09/25
When we last pushed the Spanish blood plasma giant Grifols’ (BUY ; Spain) investment case in May 2024, investor confidence was close to its nadir, as ...
17/09/25
The massive collapse in Novo Nordisk’s share price over the last 15 months, due to competitive concerns, pricing pressure and a few other factors, ...
25/08/25
Attractive return potential remains – Confidence slightly raised